On 29 June 2026, Health Canada approved Sevmia, a generic semaglutide made by the Canadian company Apotex, specifically for chronic weight management in patients 12 and older. It is a routine-sounding regulatory notice. It also quietly answers a question this magazine raised in July: is the multi-year wait for cheap semaglutide a fact of chemistry and law, or an accident of one country’s patent office?
To be clear about what this article is not: it is not an argument for or against taking semaglutide, and it says nothing about dose, effectiveness, or side effects. That is between a patient and their doctor. What it is about is a policy story about who gets to pay less for the same molecule, and why.
Canada now has three approved generics
Sevmia is the third generic semaglutide product Health Canada has cleared, and the first approved specifically for weight management rather than diabetes. The sequence: Dr. Reddy’s Laboratories received approval on 29 April 2026 for a diabetes-indication generic in 2mg and 4mg pens; Apotex followed on 1 May 2026 with its own diabetes-indication version; Apotex’s Sevmia, cleared 29 June 2026, is the first with a weight-management label. Health Canada says six more generic semaglutide submissions were still under review as of that date. Canada became, by its own regulator’s account, the first G7 country to approve a generic semaglutide product at all, when the Dr. Reddy’s approval landed in late April.
Health Canada’s language on why it approved the drugs is procedural, not political: authorization followed, in the agency’s words, “a thorough review of evidence provided by the company” showing the drug “meets Health Canada’s criteria for safety, efficacy and quality.” Nothing in the public record ties the approval to a policy decision about price. What changed was that a patent that used to block generic competition no longer exists in Canada, and it stopped existing years before anyone planned for that to happen.
The price gap, in the same currency the drugs are actually sold in
Brand-name Ozempic and Wegovy in Canada run to more than 450 Canadian dollars a month, according to pharmacy-chain reporting from May 2026. Apotex told reporters at the time that its generic would sell for roughly a third of that brand price. Health Canada’s own general guidance is that generic drugs in the country typically cost 45 to 90 percent less than the brand name.
Compare that with what Novo Nordisk itself lists for the same drugs in the United States, on its NovoCare pricing page: Ozempic at roughly 1,028 US dollars a month, Wegovy at roughly 1,350 US dollars a month. That is not the price after a rebate or a pharmacy benefit manager’s cut, it is the list price the company sets. Converted or not, it is several times the Canadian brand price, before anyone gets near a Canadian generic.
Fatosphere reported in July, in “Fat and Poor: The GLP-1 Access Gap Punishes Twice,” that US patents on semaglutide don’t begin to expire until 2032, and concluded there would be “no cheap legal version for years.” That remains true for the United States specifically. It was never true everywhere, and Canada is the proof.
Why Canada, and why by accident
The Canadian patent that would have blocked generic semaglutide, CA 2,601,784 (“Acylated GLP-1 Compounds”), did not expire on schedule. It lapsed because a maintenance fee, a routine annual payment of 250 Canadian dollars, rising to 450 dollars with a late penalty, went unpaid. The last payment on record was made on 23 October 2018. Canadian patent law gives a lapsed patent a “period of reversal” during which the fee can still be paid to bring it back to life. That window closed on 31 August 2020. After that date, the patent was gone for good, more than a decade before Novo Nordisk’s active-ingredient protection would otherwise run out in the US (2032) or the EU and Japan (2031).
Novo Nordisk has since described the missed payment as a strategic choice rather than an oversight. The documented paper trail, a specific fee amount, a specific missed date, a specific expired deadline for reinstatement, is the part that is independently verifiable. The company’s own retrospective framing of why it let that deadline pass is the company’s account of its own decision, made after the fact, and this article treats it as exactly that: their characterization, not an independently confirmed motive.
One caveat worth keeping in view: a separate Certificate of Supplementary Protection tied to the drug’s device or formulation has a listed expiry date of 20 March 2026, with a term that can extend to 20 March 2028. That is a narrower, different kind of protection than the base compound patent that lapsed in 2020, and it is one reason regulatory and commercial clarity in Canada is still settling even as three generic products are already approved.
What this does and doesn’t prove
It proves that the timeline Fatosphere described in July, patents holding until the early 2030s, therefore no affordable legal semaglutide until then, was a description of the United States, not of pharmaceutical patent law as such. A single missed payment in one country changed that country’s timeline by more than a decade. Nothing about the drug, the science, or global patent treaties required that outcome; a filing office in Ottawa and a calendar did.
It does not prove that Canada’s accident will repeat itself anywhere else. Germany’s and the rest of the EU’s active-ingredient patents are separately filed and, per current reporting, run to 2031 regardless of what happened in Canada; Fatosphere has already covered how France and Germany diverge on reimbursing semaglutide even before patents are the issue (see “Covered in France, ‘Lifestyle’ in Germany”). Canadian generic supply is also not yet evenly available: the pharmaceutical supply-chain group Vital told reporters in May that availability “may vary across regions as products move through the supply chain,” and Sevmia’s weight-management approval is only weeks old as this goes to press.
And it says nothing about whether cheaper access changes the underlying stigma this magazine covers elsewhere: who gets treated as making a legitimate medical choice, who gets treated as having cheated, and whether a lower price tag closes that gap or just moves it. That is a different question, and one Canada’s patent office did not answer.
What this piece is not
This is a report on patent history and drug pricing, not medical or financial advice, and not a recommendation for or against taking semaglutide. It makes no claim about dosing, effectiveness, or safety, and no before-and-after comparison of any kind. Canadian prices and availability described here should not be assumed to apply outside Canada, and nothing here should be read as advice to import or order medication across borders.
Sources: Health Canada news release, “Third generic semaglutide product approved for weight management,” 29 June 2026; Pearce IP, “First Generic Ozempic® (Semaglutide) Approved in Canada for Dr Reddy’s & Apotex,” 29 April 2026; Global News, reporting on generic semaglutide reaching Canadian pharmacies, May 2026; Drug Discovery Trends, “Canada approves generic semaglutide from Dr. Reddy’s, a G7 first enabled by Novo Nordisk’s lapsed CA$250 patent”; GoodRx, Wegovy and Ozempic cost overview citing Novo Nordisk NovoCare list prices, 2026; Fatosphere, “Fat and Poor: The GLP-1 Access Gap Punishes Twice,” July 2026. Read 27 September 2026.